je.st
news
Tag: drug
J&J says its diabetes drug should have same survival edge as Lilly's
2015-10-13 19:12:33| Biotech - Topix.net
REUTERS: Johnson & Johnson said the proven ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the entire class of drugs, including J&J's own approved Invokana treatment. Dominic Caruso, J&J's chief financial officer, on Tuesday gave his optimistic view of the new drug class, called SGLT2 inhibitors, during a conference call with industry analysts to discuss the company's third-quarter earnings.
Tags: drug
edge
survival
diabetes
Bile Acid Reference Standards aid drug development.
2015-10-13 14:31:07| Industrial Newsroom - All News for Today
Cerilliant® Snap-N-Spike® solutions include most routinely tested bile acids and their stable-labeled internal standards. Certified reference materials consist of lithocholic acid, taurocholic acid, and native and deuterium-labeled analogs of cholic acid, chenodeoxycholic acid, deoxycholic acid, and ursodeoxycholic acid. Mass spectrometry-based analyses of bile acids are performed in neonatal screening of inborn errors of BA synthesis and therapeutic monitoring of patient responses to therapy.
Tags: development
reference
standards
drug
Eli Lilly to stop study of heart disease drug evacetrapib
2015-10-12 18:15:55| Biotech - Topix.net
Shares of Eli Lilly plunged Monday after the drugmaker said it would stop developing a heart disease treatment that had advanced deep into clinical testing. The Indianapolis company said researchers cited a lack of effectiveness, not safety concerns, in recommending an end to late-stage research on the drug, evacetrapib.
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now ...
2015-10-10 05:30:50| Biotech - Topix.net
In the world of biopharma, it doesn't take long for a company to copy or mimic a popular, successful drug. In fact, for some less-common diseases, the industry realizes that merely sharing the revenue generated by a small niche may not even be worth the effort, meaning those rare or difficult-to-treat diseases often go completely unaddressed.
FDA expands lung cancer approval for Bristol-Myers' drug
2015-10-10 01:17:07| Biotech - Topix.net
The U.S. Food and Drug Administration on Friday expanded its approval of Bristol-Myers Squibb Co's immunotherapy drug Opdivo for patients with an additional form of advanced lung cancer. The agency said Opdivo may now be used in patients with non-squamous non-small cell lung cancer whose disease has progressed during or after platinum-based chemotherapy.
Tags: drug
approval
cancer
lung
Sites : [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] next »